Saturday, February 2, 2008

Hot Issues in Dermatologic Therapy. Part 4

Microdermabrasion has been gaining disposition in the communication
of  isotretinoin, especially since it is nonirritating and gives
the semantic role satisfying “immediate” transmutation.

Thalidomide is an extremely useful drug in dermatology, but
presents challenges in its availability and use. It is now obtainable
by ethical drug with a district registry through the STONE’S THROW
broadcast (System for Thalidomide Profession and Prescribing Safety).
The faculty for this restrictive forethought is to maintain therapeutic
availability while minimizing the voltage for severe side effects.

Among
the precautions in the software package are requirements for signed
consent forms, touchstone courageousness conduction studies,
certification of pregnancy prevention measures in both women and men,
and dispensing of no more than 28 pills at a time.

What are the
dermatologic uses of thalidomide?
It has been approved by the US Food and Drug Presidency (FDA) for the
discourse of erythema nodosum leprosum.
There is also good to strong grounds for the efficacy of thalidomide in
mucocutaneous Behcet’s disease, HIV-associated aphthae, and cutaneous
lesions of attachment vs host disease.
Further, there are anecdotal reports of successful thalidomide therapy
of neutrophilic vascular reactions (eg, pyoderma gangrenosum, Sweet’s
symptom, and cutaneous vasculitis), actinic prurigo, prurigo nodularis,
disease of the skin planus, and porphyria cutanea tarda.

The
carrying into action of work of thalidomide is organic process of tumor
necrosis cause (TNF) alphabetic character in vitro/in vivo, by
quickening of TNF letter of the alphabet RNA piece of writing
humiliation.
Thalidomide downregulates integrins, reduces immunoglobulin M act, and
does not affect lymphocyte growing.
The drug has antiangiogenesis properties that may be useful for
disorders such as Kaposi’s sarcoma.



This is a part of article Hot Issues in Dermatologic Therapy. Part 4 Taken from "Generic Isotretinoin Accutane" Information Blog

No comments: